1594. Evaluating Clinical Outcomes of an Alternative Cefepime Dosing Regimen as Empiric Antibiotic Therapy in Hospitalized Adults with Febrile Neutropenia
Session: Poster Abstract Session: Viruses and Bacteria in Immunocompromised Patients
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • 1594_IDWPOSTER.pdf (228.7 kB)
  • Background: A cefepime dosing regimen of 1 gram every 6 hours (1g Q6h) has shown to provide similar exposure above the target minimum inhibitory concentration than the higher FDA-approved regimen of 2g Q8h for febrile neutropenia. We hypothesize clinical outcomes among patients receiving either dosing strategy will be similar.

    Methods: A retrospective chart review of hospitalized patients who received cefepime for documented febrile neutropenia over a two-year period was performed. Patients were grouped based on cefepime dosing strategy: 1g Q6h vs 2g Q8h. The primary objective was to compare time to defervescence after cefepime initiation. Secondary objectives looked at all-cause and infection-related 30-day mortality, duration of therapy, and length of stay (LOS).

    Results: Seventy-five patients in each arm were included. There were no differences in baseline age or severity of illness between groups. There was no difference in the primary objective as average time to defervescence was similar between the 1g Q6h and 2g Q8h groups (85.9 h vs 89.7 h: p= 0.206), respectively.  Additionally, no differences were found in the secondary objectives including all-cause 30-day mortality (6.7% vs 9.3%: p=0.547), duration of therapy (95.7 h vs 99.1 h: p=0.174), or LOS (9 vs 7 days: p=0.251).

    Conclusion: The regimen of cefepime 1g Q6h provides similar clinical outcomes as the traditional FDA-approved 2g Q8h regimen in the treatment of febrile neutropenia. The lower total daily dose will result in less drug exposure and a potential decreased risk of cefepime-related adverse drug events.

    Manuela Haiduc, PharmD, Derek Bremmer, PharmD, BCPS, Monank Patel, PharmD, BCPS, BCOP, Thomas Walsh, MD and Matthew Moffa, DO, Allegheny Health Network, Pittsburgh, PA

    Disclosures:

    M. Haiduc, None

    D. Bremmer, None

    M. Patel, None

    T. Walsh, None

    M. Moffa, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.